Medicine
Tyzavan 500 mg/100 mL injection
Tyzavan 500 mg/100 mL injection is a prescription medicine containing Vancomycin for intravenous use, marketed by Hikma Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 15°C to 25°C (59°F to 77ºF), in original package.
Key facts
- Active ingredient (INN)
- Vancomycin
- Brand
- Tyzavan
- Strength
- 500 mg/100 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 6 bags of 100 mL, 12 bags of 100 mL
- Marketing authorisation holder
- Hikma Pharmaceuticals
- Manufacturer
- Hikma Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 15°C to 25°C (59°F to 77ºF), in original package.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A07AA09 Vancomycin
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 October 2025
- Identifiers
- RxCUI 1807508, 1807510, 1807511 +7DailyMed set ID 72e9c5e2-07cc-4a8b-ba64-b2e7619ea560NDC 0143-9471Application NDA211962
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 6 bag in 1 carton / 100 mL in 1 bag | 0143-9471-06 | Hikma Pharmaceuticals | 17 October 2025 |
| 12 bag in 1 carton / 100 mL in 1 bag | 0143-9471-12 | Hikma Pharmaceuticals | 17 October 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 15 April 1986 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Vancomycin 500 mg/100 mL injection.
Other strengths and forms of Vancomycin
Clinical summary
Vancomycin is a glycopeptide antibacterial indicated for the treatment of Clostridioides difficile -associated diarrhea, among other approved uses. It is available as powder for injection, injection and capsules for intravenous, oral and intravitreal use. MedsAcross supplies Vancomycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about VancomycinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- vancomycin hydrochloride prescribing information (ANI Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Tyzavan 500 mg/100 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.